Skip to main content

Advertisement

SpringerLink
Log in

Blinding, pragmatism, and the PRECIS-2 tool for designing and assessing randomized trials

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schwartz D, Lellouch J (2009) Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 62(5):499–505

    Article  Google Scholar 

  2. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M (2015) The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 350:h2147. https://doi.org/10.1136/bmj.h2147

    Article  PubMed  Google Scholar 

  3. Dal-Ré R (2020) The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-020-03030-8

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Studies in Family Medicine, Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, Ontario, London, Canada

    Merrick Zwarenstein & Alison Howie

Authors
  1. Merrick Zwarenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alison Howie
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

This work was conceived by MZ who wrote the first draft and edited the final draft. AH added ideas and edited the final draft.

Corresponding author

Correspondence to Merrick Zwarenstein.

Ethics declarations

Conflict of interest

MZ declares an NIH funded consultancy on trial design to the National Cancer Institute, USA. No other conflicts.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zwarenstein, M., Howie, A. Blinding, pragmatism, and the PRECIS-2 tool for designing and assessing randomized trials. Eur J Clin Pharmacol 77, 1069–1070 (2021). https://doi.org/10.1007/s00228-020-03078-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-020-03078-6

Search

Navigation